Molecular and contextual markers of hepatitis C virus and drug abuse

Molecular Diagnosis and Therapy

Volumn 13, Issue 3, 2009, Pages 153-179

  Shapshak, Paul ^a,n   Somboonwit, Charurut ^a,b   Drumright, Lydia N ^c   Frost, Simon D W ^d   Commins, Deborah ^e   Tellinghuisen, Timothy L ^f   Scott, William K ^g   Duncan, Robert ^g   McCoy, Clyde ^g   Page, J Bryan ^g,h   Giunta, Brian ^a   Fernandez, Francisco ^a   Singer, Elyse ⁱ   Levine, Andrew ⁱ   Minagar, Alireza ^j   Oluwadara, Oluwadayo ^k,l   Kotila, Taiwo ^m   Chiappelli, Francesco ^k   Sinnott, John T ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b Clinical Research Unit   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f SCRIPPS RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^h Department of Biology   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j Louisiana State University School of Medicine Shreveport   (United States)

^k UCLA SCHOOL OF DENTISTRY   (United States)

^l UNIVERSITY OF IBADAN   (Nigeria)

^m UNIVERSITY OF IBADAN   (Nigeria)

ⁿ UNIVERSITY OF SOUTH FLORIDA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

CASE MANAGEMENT; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; DRUG ABUSE; ENVIRONMENTAL FACTOR; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS C; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INFECTION PREVENTION; INFECTION RISK; INTRAVENOUS DRUG ADMINISTRATION; MIXED INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; REGULATORY T LYMPHOCYTE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEXUAL TRANSMISSION; SINGLE STRAND CONFORMATION POLYMORPHISM; SOCIAL BEHAVIOR; SOCIAL DISCRIMINATION; SOCIAL ISOLATION; VIRUS DETECTION; VIRUS LOAD; VIRUS TRANSMISSION;

HEPATITIS C VIRUS;

ANIMALS; BIOLOGICAL MARKERS; HEPACIVIRUS; HEPATITIS C; HUMANS; SUBSTANCE-RELATED DISORDERS;

EID: 68549128648     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/bf03256323     Document Type: Review

References (367)

1. Edlin BR, Kresina TF, Raymond DB, et al. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis 2005; 40 Suppl. 5: S276-85
2. Neuman MG, Monteiro M, Rehm J. Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses. Subst Use Misuse 2006; 41: 1395-1463 (Pubitemid 44472465)
3. US Department of Labor, Occupational Safety and Health Administration. Healthcare wide hazards: bloodborne pathogens [online]. Available from URL: http://www.osha.gov/SLTC/etools/hospital/hazards/bbp/bbp.html [Accessed 2009 May 19]
4. Edlin BR, Irwin KL, Faruque S, et al., for the Multicenter Crack Cocaine and HIV Infection Study Team. Intersecting epidemics: crack cocaine use and HIV infection among inner-city young adults. N Engl J Med 1994; 331: 1422-1427
5. Lauer GM, Walker BD. Hepatitis C infection. N Engl J Med 2001; 345: 41-52
6. McCoy CB, Metsch LR, Collado-Mesa F, et al. The prevalence of HIV-1 and HCV among injection drug users who use high-risk inner-city locales in Miami, Florida. Mem Inst Oswaldo Cruz 2004; 99: 789-793
7. Simmonds P. The origin and evolution of hepatitis viruses in humans. J Gen Virol 2001; 82: 693-712 (Pubitemid 32280027)
8. Thorpe LE, Ouellet LJ, Hershow R, et al. Risk of HCV infection among young adult injection drug users who share injection equipment. Am J Epidemiol 2002; 155 (7): 645-653 (Pubitemid 34246097)
9. Hagan H, Thiede H,Weiss NS, et al. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 2001; 91: 42-46 (Pubitemid 32049265)
10. Hagan H. HCV transmission dynamics in injection drug users. Subst Use Misuse 1998; 33: 1197-2120
11. Fitzmaurice K, Klenerman P. Cellular immunity and acute hepatitis C infection. Curr Pharm Des 2008; 14: 1666-1677 (Pubitemid 351998591)
12. Madhava V, Burgess C, Drucker E. Epidemiology of chronic HCV infection in sub-Saharan Africa. Lancet Infect Dis 2002; 2: 293-302 (Pubitemid 34464740)
13. Parham P. NK cells lose their inhibition. Science 2004; 305: 786-787
14. Korber B, Muldoon M, Theiler J, et al. Timing the ancestor of the HIV-1 pandemic strains. Science 2000; 288: 1789-1796 (Pubitemid 30399011)
15. Alter MJ, Kruszon-Moran D, Nainon OV, et al. The prevalence of HCV infection in the US: 1988-1994. N Engl J Med 1999; 341: 556-562
16. Armstrong GL, Wasley AM, Simard EP, et al. The prevalence of HCV infection in the US, 1999 through 2002. Ann Int Med 2006; 144: 705-714
17. Zhang T, Li Y, Ho WZ. Drug abuse, innate immunity and HCV. Rev Med Virol 2006; 16: 311-327
18. Deuffic-Burban S, Poynard T, Sulkowski MS, et al. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepatitis 2007; 14 (2): 107-115 (Pubitemid 46146705)
19. Golub ET, Bareta JC, Mehta SH, et al. Correlates of unsafe syringe acquisition and disposal among injection drug users in Baltimore, Maryland. Subst Use Misuse 2005; 40 (12): 1751-1764
20. Diaz T, Des Jarlais DC, Vlahov D, et al. Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City. Am J Public Health 2001; 91 (1): 23-30 (Pubitemid 32049262)
21. Diaz RS, Pardini R, Catroxo M, et al. HIV-1 superinfection is not a common event. J Clin Virol 2005; 33: 328-330 (Pubitemid 40982524)
22. Lorvick J, Kral AH, Seal KH, et al. Duration of hepatitis C among injection drug users in San Francisco, Calif. Am J Public Health 2001; 91: 46-47 (Pubitemid 32049266)
23. SteinMD,Maksad J, Clarke J, et al. Hepatitis C disease among injection drug users: knowledge, perceived risk, and willingness to receive treatment. Drug Alcohol Depend 2001; 61: 211-215 (Pubitemid 32119301)
24. Cheung R. Epidemiology of hepatitis C virus infection in American veterans. Am J Gastroenterol 2000; 95: 740-747 (Pubitemid 30123913)
25. Thomas DL, Astemborski J, Rai RM, et al. The natural history of HCV infection: host, viral, and environmental factors. JAMA 2000; 284: 450-456 (Pubitemid 30484478)
26. Patrick DM, Tyndall MW, Cornelisse PGA, et al. Incidence of HCV infection among IDUs during an outbreak of HIV infection. CMAJ 2001; 165: 889-895
27. Amiri M, RezvaniM, Jafari SR. Prevalence of HCV infection and risk factors of drug using prisoners in Guilan province. East Mediterr Health J 2007; 13: 250-256
28. Shapatava E, Nelson KE, Tsertsvadze T, et al. Risk behaviors and HIV, hepatitis B, and hepatitis C seroprevalence among injection drug users in Georgia. Drug Alcohol Depend 2006; 82 Suppl. 1: S35-8 (Pubitemid 43850175)
29. Garfein RS, Doherty MC, Monterroso ER, et al. Prevalence and incidence of HCV infection among young adult injection drug users. J Acquir Immune Defic Syndr 1998; 18 Suppl. 1: S11-9
30. Des Jarlais DC, Friedman SR, Stoneburner RL. HIV infection and intravenous drug use: critical issues in transmission dynamics, infection outcomes, and prevention. Rev Infect Dis 1988; 10: 152-157
31. Hahn JA, Page-Shafer K, Ford J, et al. Traveling young injection drug users at high risk for acquisition and transmission of viral infections. Drug Alcohol Depend 2008 Jan 11; 93 (1-2): 43-50 (Pubitemid 350236588)
32. Amon JJ, Garfein RS, Ahdieh-Grant L, et al. Prevalence of HCV infection among IDUs in the US, 1994-2004. Clin Inf Dis 2008; 46: 1852-1858
33. Wasley A, Grytdal S, Gallagher K. Surveillance for acute viral hepatitis - United States, 2006. MMWR Morb Mortal Wkly Rep 2008; 57 (SS-2) [online]. Available from URL: http://www.cdc.gov/mmwr/PDF/ss/ss5702.pdf [Accessed 2009 Jun 11]
34. Shannon K, Rusch M, Morgan R, et al. HIV and HCV prevalence and gender-specific risk profiles of crack cocaine smokers and dual users of injection drugs. Subst Use Misuse 2008; 43: 521-534
35. Garfein RS, Vlahov D, Galai N, et al. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996; 86: 655-661 (Pubitemid 26145477)
36. Garten RJ, Lai S, Zhang J, et al. Rapid transmission of HCV among young injecting heroin users in Southern China. Int J Epidemiol 2004; 33: 182-188 (Pubitemid 38500175)
37. Soto B, Rodrigo L, Garcia-Bengoechea M, et al. Heterosexual transmission of hepatitis C virus and the possible role of coexistent human immunodeficiency virus infection in the index case: a multicentre study of 423 pairings. J Intern Med 1994; 236: 515-519 (Pubitemid 24340008)
38. Wyld R, Robertson JR, Brettle RP, et al. Absence of hepatitis C virus transmission but frequent transmission of HIV-1 from sexual contact with doubly-infected individuals. J Infect 1997; 35: 163-166 (Pubitemid 27464686)
39. Gabrielli C, Zannini A, Corradini R, et al. Spread of hepatitis C virus among sexual partners of HCVAb positive intravenous drug users. J Infect 1994; 29: 17-22 (Pubitemid 24243106)
40. Alter MJ, Gerety RJ, Smallwood L, et al. Sporadic non-A, non-B hepatitis: frequency and epidemiology in an urban United States population. J Infect Dis 1982; 145: 886-892 (Pubitemid 12088968)
41. Thomas DL, Vlahov D, Solomon L, et al. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 1995; 74: 212-220
42. Thomas DL, Zenilman JM, Alter HJ, et al. Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore: an analysis of 309 sex partnerships. J Infect Dis 1995; 171: 768-775
43. Campbell JV, Hagan H, Latka MH, et al. The STRIVE Project: high prevalence of alcohol use among HCV antibody positive injection drug users in three US cities. Drug Alcohol Depend 2006; 81: 259-265 (Pubitemid 43152452)
44. Hepburn MJ, Hepburn LM, Cantu NS, et al. Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med 2004; 117: 163-168 (Pubitemid 39055867)
45. Yu L, Sloane DA, Guo C, et al. Risk factors for primary hepatocellular carcinoma in black and white Americans in 2000. Clin Gastroenterol Hepatol 2006 Mar; 4 (3): 355-360
46. Taylor A, Hutchinson SJ, Gilchrist G, et al. Prevalence and determinants of hepatitis C virus infection among female drug injecting sex workers in Glasgow. Harm Reduction J 2008; 5: 11-17 (Pubitemid 351594156)
47. Alter MJ, Coleman PJ, Alexander WJ, et al. Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis.JAMA 1989; 262: 1201-1205 (Pubitemid 19206696)
48. Osmond DH, Charlebois E, Sheppard HW, et al. Comparison of risk factors for hepatitis C and hepatitis B virus infection in homosexual men. J Infect Dis 1993; 167: 66-71 (Pubitemid 23002838)
49. Osmond DH, Padian NS, Sheppard HW, et al. Risk factors for hepatitis C virus seropositivity in heterosexual couples. JAMA 1993; 269: 361-365 (Pubitemid 23018074)
50. Feldman JG, Minkoff H, Landesman S, et al. Heterosexual transmission of hepatitis C, hepatitis B, and HIV-1 in a sample of inner city women. Sex Transm Dis 2000; 27: 338-342 (Pubitemid 30439548)
51. Ruiz-Sancho A, Barreiro P, Castellares C, et al. Outbreak of syphilis, but not of acute hepatitis C, among HIV-infected homosexual men in Madrid. HIV Clin Trials 2007; 8: 98-101 (Pubitemid 46953300)
52. Buffington J, Murray PJ, Schlanger K, et al. Low prevalence of hepatitis C virus antibody in men who have sex with men who do not inject drugs. Public Health Rep 2007; 122 Suppl. 2: 63-67 (Pubitemid 47443834)
53. Cohen DE, Russell CJ, Golub SA, et al. Prevalence of hepatitis C virus infection among men who have sex with men at a Boston community health center and its association with markers of high-risk behavior. AIDS Patient Care STDS 2006; 20: 557-564
54. Van de Laar TJ, van der Bij AK, Prins M, et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis 2007; 196: 230-238 (Pubitemid 47047462)
55. McCoy CB, Shapshak P, Rivers JE, et al. The risks of injection practices and compliance to risk reduction protocols in the prevention of HIV-1 among injecting drug users. J AIDS 1994; 7: 773-776
56. McCoy CB, Shapshak P, Shah SM, et al. HIV-1 prevention: interdisciplinary studies and review on efficacy of bleach and compliance to bleach prevention protocols, National Research Council and Institute of Medicine. Washington, DC: National Academy Press, 1994: 255-283
57. Hagan H, Thiede H, Des Jarlais D. HIV/HCV co-infection in drug users: risk behavior and prevention. AIDS 2005; 19: S199-207 (Pubitemid 41682188)
58. Holly H, Thiede H. Does bleach disinfection of syringes help prevent HCV transmission. Epidemiology 2003; 14: 628-629
59. Inciardi JA, Page JB. Drug sharing among intravenous drug users. AIDS 1991; 5 (6): 772-773
60. Friedman SR, Kang SY, Deren S, et al. Drug-scene roles and HIV risk among Puerto Rican injection drug users in east Harlem, New York and Bayamon, Puerto Rico. J Psychoact Drugs 2002; 34 (4): 363-369 (Pubitemid 36135263)
61. Chitwood D, McCoy CB, Inciardi JA, et al. HIV seropositivity of needles from shooting galleries in South Florida. Am J PublicHealth 1990; 80: 150-152 (Pubitemid 20034975)
62. Des Jarlais DC, Friedman SR. Shooting galleries and AIDS: infection probabilities and 'tough' policies. Am J Public Health 1990; 80 (2): 142-145
63. Hopkins W. Needle sharing and street behavior in response to AIDS in New York City. In: Battjes RJ, Pickens RW, editors. Needle sharing among IVDUs: national and international perspectives. NIDA Research Monograph No. 80. Washington, DC: National Institute on Drug Abuse, 1988: 18-27
64. Sattar SA, Tetro J, Springthorpe VS, et al. Preventing the spread of hepatitis B and C viruses: where are germicides relevant? Am J Infect Control 2001; 29: 187-197
65. Shapshak P,McCoy CB, Rivers J, et al. Bleach effectively inactivates HIV-1 at short time intervals. J AIDS 1993; 6: 218-219
66. Shapshak P, McCoy CB, Shah SM, et al. Preliminary laboratory studies on inactivation ofHIV-1 in needles and syringes containing infected blood using undiluted household bleach. J AIDS 1994; 7: 754-759 (Pubitemid 24195841)
67. Shapshak P, Fujimura RK, Page JB, et al. HIV-1RNAload in needle/syringes from shooting galleries in Miami: a preliminary laboratory report. Drug Alcohol Depend 2000; 58: 153-157
68. Hagan H, Jarlais DC, Friedman SR, et al. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. Am J Public Health 1995; 85 (11): 1531-1537
69. Hagan H, McGough JP, Thiede H, et al. Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol 1999; 149: 203-213 (Pubitemid 29053159)
70. Koester S, Glanz J, Baron A. Drug sharing among heroin networks: implications for HIV and hepatitis B and C prevention. AIDS Behav 2005; 9: 27-39 (Pubitemid 40562182)
71. Koester S, Heimer R, Baron AE. Re: ''risk of HCV among young adult injection drug users who share injection equipment'' [comment on Am J Epidemiol 2002; 155: 645-53]. Am J Epidemiol 2003; 157: 376-378
72. Koester S, Booth R, Wiebel W. The risk of HIV transmission from sharing water, drug-mixing containers and cotton filters among intravenous drug users. Int J Drug Policy 1990; 1 (6): 28-30
73. McCoy CB, Metsch L, Chitwood D, et al. Parenteral transmission of HIV among IDUs: assessing the frequency of multi-person use of needles, syringes, cookers, cotton, and water. J AIDS 1998; 18: S25-9 (Pubitemid 28304465)
74. Hagan H, Des Jarlais DC. HIV and HCV infection among injection drug users. Mount Sinai J Med 2000; 67: 423-428
75. Page JB, Shapshak P, Duran EM, et al. Detection of HIV-1 in injection paraphernalia: risk in an era of heightened awareness. AIDS Patient Care STDs 2006; 20: 576-585 (Pubitemid 44769205)
76. Strathdee SA, Vlahov D. The effectiveness of needle exchange programs: a review of the science and policy. AIDScience 2001; 1: 1-31
77. Mansson AS, Mansson AS, Moestrup T, et al. Continued transmission of hepatitis B and C viruses, but no transmission of human immunodeficiency virus among intravenous drug users participating in a syringe/needle exchange program. Scand J Infect Dis 2000; 32: 253-258 (Pubitemid 30599214)
78. Lankenau S, Clatts M. Patterns of polydrug use among ketamine injectors in New York City. Subst Use Misuse 2005; 40: 1381-1397 (Pubitemid 41098799)
79. Macías J, Palacios RB, Claro E, et al. High prevalence of hepatitis C virus infection among noninjecting drug users: association with sharing the inhalation implements of crack. Liver Int 2008; 28: 781-786 (Pubitemid 351818639)
80. Aaron S, McMahon JM, Milano D, et al. Intranasal transmission of HCV: virological and clinical evidence. Clin Inf Dis 2008; 47: 931-934
81. Neaigus A, Gyarmathy VA, Zhao M, et al. Sexual and other noninjection risks for HBV and HCV seroconversions among noninjecting heroin users. J Infect Dis 2007; 195: 1052-1061 (Pubitemid 46452112)
82. Hellard ME, Hocking JS, Crofts N. The prevalence and the risk behaviours associated with the transmission of hepatitis C virus in Australian correctional facilities. Epidemiol Infect 2004; 132: 409-415 (Pubitemid 38714116)
83. European Pediatric HCV Network. A significant sex - but not elective cesarean section - effect on mother-to-child transmission of HCV infection. J Infect Dis 2005; 192: 1872-1879
84. Girou E, Chevaliez S, Challine D, et al. Determinant roles of environmental contamination and noncompliance with standard precautions in the risk of HCV transmission in a hemodialysis unit. Clin Infect Dis 2008; 47: 1-7
85. Pares A, Berrera JM, Caballeria J, et al. Hepatitis C virus antibodies in chronic alcoholic patients: association with severity of liver injury. Hepatology 1990; 12: 1295-1301
86. Thomas DL, Vlahov D, Solomon L, et al. Correlates of hepatitis C infections among injection drug users. Medicine (Baltimore) 1995 Jul; 74 (4): 212-220
87. Haley RW, Fischer RP. Commercial tattooing as a potentially important source of hepatitis C infection: clinical epidemiology of 626 consecutive patients unaware of their hepatitis C serologic status. Medicine (Baltimore) 2001 Mar; 80 (2): 134-151
88. Xia X, Luo J, Bai J, et al. Epidemiology of hepatitis C virus infection among injection drug users in China: systematic review and meta-analysis. Public Health 2008 Oct; 122 (10): 990-1003
89. Russell M, Chen MJ, Nochajski TH, et al. Risky sexual behavior, bleeding caused by intimate partner violence, and hepatitis C virus infection in patients of a sexually transmitted disease clinic. Am J Public Health 2009 Apr; 99 Suppl. 1: S173-9
90. Backus LI, Phillips BR, Boothroyd DB, et al. Effects of HCV co-infection on survival in veterans with HIV treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005; 39 (5): 613-619
91. Balasubramanian A, Groopman JE, Ganju RK. Underlying pathophysiology of HCV infection in HIV-positive drug users. J Addict Dis 2008; 27 (2): 75-82
92. Bobkova MR, Samokhvalov YI, et al. Genetic variants of hepatitis C virus in HIV-infected drug users. Vopr Virusol 2002; 47 (3): 15-20
93. Chakraborty B, Valer L, De Mendoza C, et al. Failure to detect human immunodeficiency virus type 1 superinfection in 28 HIV-seroconcordant individuals with high risk of reexposure to the virus. AIDS Res Hum Retroviruses 2004; 20: 1026-1031 (Pubitemid 39369711)
94. Cooper CL. ''Liver''-ing HIV/HCV co-infected patients from antiretroviral toxicities. J Infect Dis 2007; 196: 656-660
95. Tetali S, Abrams E, Bakshi S, et al. Virus load as a marker of disease progression in HIV-infected children. AIDS Res Hum Retrov 1996; 12: 669-675 (Pubitemid 26138745)
96. Yun H, Kim D, et al. High prevalence of HBV and HCV infection among intravenous drug users in Korea. J Med Virol 2008; 80 (9): 1570-1575
97. Kleinman S, Busch MP, Korelitz JJ, et al. The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and HCV infection. Transfus Med Rev 1997; 11: 155-172 (Pubitemid 27358980)
98. Law M, Maruyama T, Lewis J, et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 2008 Jan; 14 (1):25-27
99. Gretch DR, de la Rosa C, Carothers Jr RL, et al. Assessment of hepatitis C viremia using molecular amplification technologies: correlations and clinical implications. Ann Intern Med 1995; 123: 321-330
100. Zaaijer HL, Cuypers HT, Reesink HW, et al. Reliability of polymerase chain reaction for detection of hepatitis C virus. Lancet 1993; 341: 722-724 (Pubitemid 23085179)
101. Hagan H, Thiede H, Des Jarlais DC. HCV infection among injection drug users: survival analysis of time to seroconversion. Epidemiology 2004; 15: 543-549 (Pubitemid 40416907)
102. Gottlieb GS, Hawes SE, Agne HD, et al. Lower levels of HIV RNA in semen in HIV-2 compared to HIV-1 infection: implications for differences in transmission. AIDS 2006; 20: 895-900
103. Mukherjee S, Dhawan VK. Hepatitis C: emedicine 2008 [online]. Available from URL: http://www.emedicine.com/MED/topic993.htm [Accessed 2009 May 30]
104. Strader DB, Wright T, Thomas DL, et al. American Association for the Study of Liver Diseases: diagnosis, management, and treatment of hepatitis C. Hepatology 2004 Apr; 39 (4): 1147-1171
105. Calonge N, Randhawa G. The meaning of the US Preventive Service Task Force grade I recommendation: screening for hepatitis C virus infection. Ann Intern Med 2004; 141: 718-722 (Pubitemid 39434845)
106. Busch MP, Tobler LH, Tegtmeter G, et al. Use of third generation hepatitis C virus (HCV) enzyme immunoassay (EIA) to resolve second-generation HCV EIA-reactive and to support current Food and Drug Administration guidance on HCV look back. Transfusion 2000; 40: 10-16
107. Laskus T, Radkowski M, Wang LF, et al. HCV quasispecies in patients infected with HIV-1: correlation with extra-hepatic viral replication. Virol 1998; 248: 164-171 (Pubitemid 28393940)
108. Laskus T, Radkowski M, Wang LF, et al. Uneven distribution of HCV quasispecies in tissues from subjects with end-stage liver disease: confounding effect of viral adsorption and mounting evidence for the presence of low-level extra-hepatic replication. J Virol 2000; 74: 1014-1017 (Pubitemid 30036240)
109. Maggi F, Giorgi M, Fornai C, et al. Detection and quasispecies analysis of HCV in the cerebrospinal fluid of infected patients. Neurovirology 1999; 5: 319-323 (Pubitemid 29329107)
110. Laskus T, Wilkinson J, Karim R, et al. Hepatitis C virus quasispecies in HIVinfected women: role of injecting drug use and highly active antiretroviral therapy (HAART). Hepatology 2007; 46: 359-370 (Pubitemid 47344770)
111. Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 962-973 (Pubitemid 41401136)
112. Simmonds P, Holmes EC, Cha TA, et al. Classification of hepatitis-C virus into 6 major genotypes and a series of subtypes by phylogenetic analysis of the Ns-5 region. J Gen Virol 1993; 74: 2391-2399 (Pubitemid 23332300)
113. Bukh J, Miller R, Purcell R. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995; 15: 41-45
114. Chambers TJ, Fan X, Droll DA, et al. Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic HCV infection. J Virol 2005; 79: 3071-3083 (Pubitemid 40270586)
115. Gerhardt M, Mloka D, Tovanabutra S, et al. In-depth, longitudinal analysis of viral quasispecies from an individual triply infected with late-stage human immunodeficiency virus type 1, using a multiple PCR primer approach. J Virol 2005; 79: 8249-8261 (Pubitemid 40853529)
116. Laskus T, Operskalski EA, Radkowski M, et al. Negative-strand HCV RNA in peripheral bloodmononuclear cells from anti-HCV-positive/HIV-infected women. J Infect Dis 2007; 195: 124-133 (Pubitemid 44958234)
117. Blackard JT, Sherman KE. Hepatitis C virus co-infection and superinfection. J Infect Dis 2007; 195: 519-524
118. Herring BL, Page-Shafer K, Tobler LH, et al. Frequent hepatitis C virus superinfection in injection drug users. J Infect Dis 2004; 190: 1396-1403 (Pubitemid 39334852)
119. Dove L, Phung Y, Bzowej N, et al. Viral evolution of hepatitis C in injection drug users. J Viral Hepat 2005; 12: 574-583 (Pubitemid 41532488)
120. Backmund M. Interferonbehandlung während der Entzugsbehandlung. Suchttherapie 2002; 3 Suppl. 1: S67-71
121. Kao JH, Lai MY, Chen PJ, et al. Probable reinfection with HCV in a chronic hepatitis C patient with a sustained response to combination therapy. J Formos Med Assoc 2001; 100: 824-828
122. De Mitri MS, Cassini R, Morsica G, et al. New infection with heterotypic HCV in a patient with long-term HCV eradication. Dig Liver Dis 2001; 33: 591-594
123. Asselah T, Vidaud D, Doloy A, et al. Second infection with a different HCV genotype intravenous drug user during interferon therapy. Gut 2003; 52: 900-902 (Pubitemid 36613501)
124. Dalgard O, Bjoro K, Hellum K, et al. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur Addict Res 2002; 8: 45-49 (Pubitemid 34701984)
125. Proust B, Dubois F, Bacq Y, et al. Two successive HCV infections in an intravenous drug user. J Clin Microbiol 2000; 38: 3125-3127 (Pubitemid 30640617)
126. Tscherne DM, EvansMJ, von Hahn T, et al. Superinfection exclusion in cells infected with hepatitis C virus. J Virol 2007; 81: 3693-3703 (Pubitemid 46586866)
127. Li Y, Wang X, Douglas SD, et al. CD8 T cell depletion amplifies hepatitis C virus replication in peripheral blood mononuclear cells. J Infect Dis 2005; 192: 1093-1101 (Pubitemid 41266809)
128. Wang JT, Sheu JC, Lin JT, et al. Detection of replicative form of hepatitis C virus RNA in peripheral blood mononuclear cells. J Infect Dis 1992; 166: 1167-1169
129. Muller HM, Pfaff E, Goeser T, et al. Peripheral blood leukocytes serve as a possible extra-hepatic site for hepatitis C virus replication. J Gen Virol 1993; 74: 669-676 (Pubitemid 23113370)
130. WillemsM, Peerlinck K, Moshage H, et al. Hepatitis C virus-RNAs in plasma and in peripheral blood mononuclear cells of hemophiliacs with chronic hepatitis C: evidence for viral replication in peripheral blood mononuclear cells. J Med Virol 1994; 42: 272-278 (Pubitemid 24131397)
131. Laskus T, Radkowski M, Piasek A, et al. HCV in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes/macrophages and lymphocytes. J Infect Dis 2000; 181: 442-448 (Pubitemid 30131808)
132. Marek R, Wilkinson J, Nowicki M, et al. Search for HCV negative-strand RNAsequences and analysis of viral sequences in the central nervous system: evidence of replication. J Virol 2002; 76: 600-608 (Pubitemid 34033359)
133. Krekulova L, Rehak V, Riley RW. Hepatitis C virus (HCV) 50 NC sequence variants and their association with hepatitis C risk groups. J Clin Virol 2005; 32 (4): 300-304 (Pubitemid 40386564)
134. Oh HB, Kim SO, Cha CH, et al. Identification of hepatitis C virus genotype 6 in Korean patients by analysis of 50 untranslated region using a matrix assisted laser desorption/ionization time of flight-based assay: restriction fragment mass polymorphism. J Med Virol 2008; 80 (10): 1712-1719
135. Davidson F, Simmonds P, Ferguson JC, et al. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 50 non-coding region. J Gen Virol 1995; 76: 1197-1204
136. Andonov A, Chaudary RK. Genotyping of Canadian hepatitis C virus isolates by PCR. J Clin Mictorbiol 1994; 32: 2031-2034 (Pubitemid 24222295)
137. Estaban JI, Estaban R, Viladomiu L, et al. Evaluation of antibodies to hepatitis C virus in a study of transfusion associated hepatitis. N Engl J Med 1990; 323: 1107-1111 (Pubitemid 20370732)
138. Lok AS, Gunaratnam NT. Diagnosis of hepatitis C. Hepatology 1997 Sep; 26 (3 Suppl. 1): 48-56S
139. Pawlotsky JM, Lonjon I, Hezode C, et al. What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories? Hepatology 1998; 27: 1700-1704
140. DamenM, Zaaijer HL, Cuypers HT, et al. Reliability of the third-generation recombinant immunoblot assay for hepatitis C virus. Transfusion 1995 Sep; 35 (9): 745-749
141. Fabrizi F, Martina P, V Dixit, et al. Automated RIBATM HCV strip immunoblot assay: a novel tool for the diagnosis of hepatitis C virus infection in hemodialysis patients. Am J Nephrol 2001; 21: 104-111 (Pubitemid 32453688)
142. Bluthenthal RN, Kral AH, Gee L, et al. The effect of syringe exchange use on high-risk injection drug users: a cohort study. AIDS 2000; 14: 605-611 (Pubitemid 30209702)
143. Icardi G, Ansaldi F, Bruzonne BM, et al. Novel approach to reduce the hepatitis C virus (HCV) window period: clinical evaluation of a new enzymelinked immunosorbent assay for HCV core antigen. J Clin Microbiol 2001; 39: 3110-3114 (Pubitemid 32830301)
144. Hahn JA, Page-Shafer K, Lum PJ, et al. HCV infection and needle exchange use among young injection drug users in San Francisco. Hepatology 2001; 34: 180-187 (Pubitemid 32591498)
145. Buck M. Direct infection and replication of naturally occurring hepatitis C virus genotypes 1, 2, 3 and 4 in normal human hepatocyte cultures. PLoS ONE 2008; 3 (7): e2660
146. Lindenbach BD, Evans MJ, Syder AJ, et al. Complete replication of HCV in cell culture. Science 2005; 309: 623-626
147. Gerberding JL. Incidence and prevalence of human immunodeficiency virus, hepatitis B virus, HCV, and cytomegalovirus among health care personnel at risk for blood exposure: final report from a longitudinal study. J Infect Dis 1994; 170: 1410-1417 (Pubitemid 24979098)
148. Van Ameijden EJC, VanDen Hoek JAR, Mientjes GHC, et al. Alongitudinal study on the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam. Eur J Epidemiol 1993; 9: 255-262
149. Lanford RE, Chavez D, Chisari FV, et al. Lack of detection of negative-strand HCV RNA in peripheral blood mononuclear cells and other extra-hepatic tissues by the highly strand-specific rTth reverse transcriptase PCR. J Virol 1995; 69: 8079-8083
150. Bronowicki JP, Loriot MA, Thiers V, et al. HCV persistence in human hematopoietic cells injected into SCID mice. Hepatology 1998; 28: 211-218 (Pubitemid 28300003)
151. Lerat H, Berby F, Trabaud MA, et al. Specific detection of hepatitis C virus minus strand RNA in hematopoietic cells. J Clin Invest 1996; 97: 845-851 (Pubitemid 26057104)
152. Radkowski M, Kubicka J, Kisiel E, et al. Detection of active HCV and hepatitis G virus/GB virus C replication in bone marrow in human subjects. Blood 2000; 95: 3986-3989 (Pubitemid 30412878)
153. Radkowski M, Wang LF, Vargas HE, et al. Detection of HCV replication in peripheral blood mononuclear cells after orthotopic liver transplantation. Transplantation 1998; 66: 664-666 (Pubitemid 28433854)
154. Crovatto M, Pozzato G, Zorat F, et al. Peripheral blood neutrophils from hepatitis C virus-infected patients are replication sites of the virus. Haematologica 2000; 85: 356-361 (Pubitemid 30318507)
155. Radkowski M, Nasseri J, Laskus T. HCV: variability, extrahepatic replication, and neuroinvasion. In:Goodkin K, Verma A, Shapshak P, editors. The spectrum of neuroAIDS disorders: pathophysiology, diagnosis, and treatment. Washington, DC: ASM Press, 2008: 295-311
156. Wilkinson J, Radkowski M, Laskus T. HCV neuroinvasion: identification of infected cells. J Virol 2009; 83: 1312-1319
157. Weissenborn K, Tryc AB, Heeren M, et al. Hepatitis C virus infection and the brain. Metab Brain Dis 2009; 24: 197-210
158. Aitken C, McCaw R, Jardine D, et al. Change in hepatitis C virus genotype in injecting drug users. J Med Virol 2004; 74: 543-545 (Pubitemid 39426094)
159. Backmund M, Meyer K, Edlin BR. Infrequent reinfection after successful treatment for HCV infection in IDUs. Clin Inf Dis 2004; 39: 1540-1543
160. Backmund M, Meyer K, von Zielonka M, et al. Treatment of hepatitis C infection in injection drug users. Hepatology 2001; 34: 188-193 (Pubitemid 32591499)
161. Silvestri F, Pipan C, Barillari G, et al. Prevalence of HCV infection in patients with lymphoproliferative disorders. Blood 1996; 87: 4296-4301 (Pubitemid 26152271)
162. Van Thiel DH, Anantharaju A, Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. Am J Gastroenterol 2003; 98: 2281-2288 (Pubitemid 37305371)
163. Currie SL, Ryan JC, Tracy D, et al. A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus. Drug Alcohol Depend 2008; 93: 148-154 (Pubitemid 350236602)
164. Aurora R, Donlin MJ, Cannon NA, et al. Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans. J Clin Invest 2009; 119: 225-236
165. Deren S, Kang SY, Colon HM, et al. HIV incidence among high-risk Puerto Rican drug users: a comparison of east Harlem, New York and Bayamon, Puerto Rico. J AIDS 2004; 36 (5): 1067-1074 (Pubitemid 38989373)
166. Deren S, Kang SY, Colon HM, et al. Migration and HIV risk behaviors: Puerto Rican drug injectors inNYCity and Puerto Rico.AmJ Public Health 2003; 93: 812-816
167. Deren S, Shedlin M, Decena CU, et al. Research challenges to the study of HIV/AIDS among migrant and immigrant Hispanic populations in the United States. J Urban Health: Bull NY Acad Med 2005; 82 (2 Suppl. 3): S13-25 (Pubitemid 41442964)
168. Bernier L, Bernard W, Gilles D, et al. Identification of numerous hepatitis C virus genotypes in Montreal, Canada. J Clin Microbiol 1996; 34: 2815-2818 (Pubitemid 26346509)
169. McMahon BJ, Hennessey TW, Christensen C, et al. Epidemiology and risk factors for hepatitis C in Alaska natives. Hepatology 39 (2): 325-332
170. Chiquete E, PanduroA. Low prevalence of anti-hepatitis C virus antibodies in Mexico: a systematic review. Intervirology 2007; 50 (1): 1-8
171. Dehesa-Violante M, Bosques-Padilla F, Kershenobich-Stalinkowitz D, et al. Prevalence of hepatitis C virus genotypes in Mexican patients. Rev Gastroenterol Mex 2007; 72 (4): 344-348
172. Martial J, Yoann M, Abel S, et al. HCV genotypes in the Caribbean island of Martinique: evidence for a large radiation of HCV-2 and for a recent introduction from Europe of HCV-4. J Clin Microbiol 2004 Feb; 42 (2): 784-791 (Pubitemid 38222663)
173. Bezerra CS, Lima JMC, Vilar JL, et al. Viral hepatitis C in a leading Brazilian hospital: epidemiological factors and genotyping. Braz J Microbiol 2007; 38 (4): 656-661
174. Ferreira M, Lonardoni MVC. Hepatitis C: serological and molecular diagnosis and genotype in haemophilic patients at the Regional Hemocenter of Maringa, Maringa PR Brazil. Haemophilia 2008; 14 (4): 810-815
175. da Silva CM, Costi C. High proportion of hepatitis C virus genotypes 1 and 3 in a large cohort of patients from Southern Brazil. Mem Instit Oswaldo Cruz 2007; 102 (7): 867-870
176. Perez RM, Ferraz MLG, Figueiredo MS, et al. Unexpected distribution of hepatitis C virus genotypes in patients on hemodialysis and kidney transplant recipients. J Med Virol 2003; 69: 489-494
177. Trepo C, Pradat P. Hepatitis C virus infection in Western Europe. J Hepatol 1999; 31: 80-83 (Pubitemid 30002696)
178. Tamalet C, Colson P, Tissot-Dupont H, et al. Genomic and phylogenetic analysis of hepatitis C virus isolates: a survey of 535 strains circulating in southern France. J Med Virol 2003; 71: 391-398 (Pubitemid 37176628)
179. Payan R, Roudot-Thoraval F, Marcellin P, et al. Changing of hepatitis C virus genotype patterns in France at the beginning of the third millennium: the GEMHEP GenoCII study. J Viral Hepat 2005; 12: 405-413 (Pubitemid 40961481)
180. Roman F, Hawotte K, Struck D, et al. Hepatitis C virus genotypes distribution and transmission risk factors in Luxembourg from 1991 to 2006. World J Gastroenterol 2008 Feb 28; 14 (8): 1237-1243
181. Schröter M, Zöllner B, Schäfer P, et al. Epidemiological dynamics of hepatitis C virus among 747 German individuals: new subtypes on the advance. J Clin Microbiol 2002; 40: 1866-1868
182. Hueppe D, Zehnter E. Epidemiology of chronic hepatitis C in Germany: an analysis of 10326 patients in hepatitis centres and outpatient units. Z Gastroenterol 2008; 46 (1): 34-44 (Pubitemid 351261948)
183. Van Asten L, Verhaest I, Lamzira S, et al. Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysis. J Infect Dis 2004; 189: 292-302 (Pubitemid 38147254)
184. Haushofer AC, Kopty C,Hauer R, et al. HCV genotypes and age distribution in patients of Vienna and surrounding areas. J Clin Virol 2001; 20: 41-47
185. Dal Molin G, Ansaldi F, Biagi C, et al. Changing molecular epidemiology of hepatitis C virus infection in northeast Italy. J Med Virol 2002; 68: 352-356
186. Christofidou M, Jelastopulu E, Economedes J, et al. Epidemiology of chronic hepatitis C virus infection in high risk groups. Hepat Monthly 2008; 8 (1): 11-16 (Pubitemid 351802691)
187. De Vries MJ, teRijdt B, van Nieuwkerk CMJ.Genotype distribution amongst hepatitis C patients in the Netherlands. J Med 2006; 64: 109-113
188. Van de Laar TJW, Koppelman M, van der Bij AK, et al. Diversity and origin of hepatitisCvirus infection among unpaid blood donors in the Netherlands. Transfusion 2006; 46 (10): 1719-1728 (Pubitemid 44435724)
189. De Maeght S, Henrion J. A pilot observational survey of hepatitis C in Belgium. Acta Gastroenterol Belg 2008; 71 (1): 4-8 (Pubitemid 351613478)
190. Mathei C, Wollants E, Verbeeck J, et al. Molecular epidemiology of hepatitis C among drug users in Flanders, Belgium: association of genotype with clinical parameters and with sex- and drug-related risk behaviours. Euro J Clin Microbiol Infect Dis 2005; 24: 514-522 (Pubitemid 41414000)
191. Naoumov NV. Hepatitis C virus infection in Eastern Europe. J Hepatol 1999; 31: 84-87 (Pubitemid 30002697)
192. Kalinina O, Norder H, Vetrov T, et al. Shift in predominating subtype of HCV from 1b to 3a in St. Petersburg mediated by increase in injecting drug use. J Med Virol 2001; 65: 517-524 (Pubitemid 32959078)
193. Chlabicz S, Flisiak R, Kowalczuk O, et al. Changing HCV genotypes distribution in Poland: relation to source and time of infection. J Clin Virol 2008; 42 (2): 156-159
194. Chlabicz S, Flisiak R, Kowalczuk O, et al. High prevalence of genotype 4 among hepatitis C virus-infected intravenous drug users in north-eastern Poland. J Med Virol 2008; 80 (4): 615-618 (Pubitemid 351358558)
195. Garten RJ, Zhang J, Lai S, et al. Co-infection with HIV and hepatitis C virus among injection drug users in southern China. Clin Infect Dis 2005; 41 Suppl. 1: S18-24 (Pubitemid 40867311)
196. Liu JY, Lin HH, Liu YC, et al. Extremely high prevalence and genetic diversity of hepatitis C virus infection among HIV-infected injection drug users in Taiwan. Clin Infect Dis 2008; 46 (11): 1761-1768 (Pubitemid 351715233)
197. Wu JS, Lee HF, Hsiau HL, et al. Genotype distribution of hepatitis C virus infection in Taiwan. J Med Virol 1994; 44: 74-79 (Pubitemid 24288129)
198. Deng XZ, Zhang Y. Hepatitis C virus genotyping and serum anti-F antibody detection of HCV patients in the south of Jiangsu province of China. Prog Post-Genome Technol 2007; 10: 366-369
199. Liu PP, Xiang KL, Yu J, et al. Molecular epidemiology of human immunodeficiency virus type 1 and hepatitis C virus in former blood donors in central China. AIDS Res Hum Retrovir 2008; 24 (1): 1-6
200. Peng JS, Wang X, Liu MQ, et al. Genetic variation of hepatitis C virus in a cohort of injection heroin users in Wuhan, China. Virus Res 2008; 135 (1): 191-196
201. Xia XS, Lu L. The unique HCV genotype distribution and the discovery of a novel subtype 6u among IDUs co-infected with HIV-1 in Yunnan, China. J Med Virol 2008; 80 (7): 1142-1152 (Pubitemid 351705992)
202. McOmish F, Yap PL, Dow BC, et al. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol 1994; 32 (4): 884-892 (Pubitemid 24100056)
203. Sunanchaikarn S, Theamboonfers A. Seroepidemiology and genotypes of hepatitis C virus in Thailand. Asian Pac J Allergy Immunol 2007; 25: 175-182 (Pubitemid 350081449)
204. Khan A, Kurbanov F, Kondo M, et al. Epidemiological and clinical evaluation of hepatitis B, hepatitis C, and delta hepatitis viruses in Tajikistan. J Med Virol 2008; 80 (2): 268-276
205. Altuglu I, Soyler I, Ozacar T, et al. Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection inWestern Turkey. Int J Infect Dis 2008; 12 (3): 239-244 (Pubitemid 351539094)
206. Verma V, Chakravarti A. Genotypic characterization of hepatitis C virus and its significance in patients with chronic liver disease from Northern India. Diag Microbiol Infect Dis 2008; 61 (4): 408-414 (Pubitemid 351970643)
207. Das BR, Kundu B, Khandapkar R, et al. Geographical distribution of hepatitis C virus genotypes in India. Indian J Pathol Microbiol 2002 Jul; 45 (3): 323-328
208. Raja NS, Khalid AJ. Epidemiology of hepatitis C virus infection in Pakistan. J Microbiol Immunol Infect 2008; 41: 4-8 (Pubitemid 351792115)
209. Idrees M, Riazuddin S. Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission. BMC Infect Dis 2008; 8: 69-75 (Pubitemid 351803135)
210. Kabir A, Alavian SM, KeyvaniH.Distribution of hepatitis C virus genotypes in patients infected by different sources and its correlation with clinical and virological parameters: a preliminary study. Comp Hepatol 2006; 5: 4 (Pubitemid 44566860)
211. Samimi-Rad K, Nategh R, Malekzadeh R, et al. Molecular epidemiology of hepatitis C virus in Iran as reflected by phylogenetic analysis of the NS5B region. J Med Virol 2004; 74: 246-252 (Pubitemid 39150391)
212. Somi MH, Keivani H, Ardalan MR, et al. Hepatitis C virus genotypes in patients with end-stage renal disease in East Azerbaijan, Iran. Saudi J Kidney Dis Transpl 2008; 19 (3): 461-465
213. Shobokshi OA, Serebour FE, Skakni L, et al. Hepatitis C genotypes and subtypes in Saudi Arabia. J Med Virol 1999; 58: 44-48 (Pubitemid 29172119)
214. Osobo A. Hepatitis C virus genotypes in theKingdom of Saudi Arabia. Saudi Med J 2002; 23: 7-12 (Pubitemid 34187712)
215. Pacsaa AS, Al-Muftib T, Chugha G, et al. Genotypes of hepatitis C virus in Kuwait. Med Princ Pract 2001; 10: 55-57
216. Ramia S,Koujssa S, Taher A, et al. Hepatitis-C-virus genotypes and hepatitis- G-virus infection in Lebanese thalassaemics. Ann Trop Med Parasitol 2002; 96: 197-202 (Pubitemid 34298955)
217. Benani A, El-Turk J, Benjelloun S, et al. HCV genotypes in Morocco. JMed Virol 1997; 52: 396-398
218. Ndong-Atome GR, Makuwa M, Njuoum R, et al. Hepatitis C virus prevalence and genetic diversity among pregnant women in Gabon, Central Africa. BMC Infect Dis 2008; 8: 82 (Pubitemid 351998107)
219. Ray S, Ray R, Carella A, et al. Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis 2000; 182: 698-707 (Pubitemid 30695363)
220. Mudawi HMY, Smith HM, Fletcher IA, et al. Prevalence and common genotypes of HCV infection in Sudanese patients with hepatosplenic schistosomiasis. J Med Virol 2007; 79 (9): 1322-1324
221. Razafindratsimandresy R, Dubot A, Ramarakoto CE, et al. Hepatitis C virus infection and genotypes in Antananarivo, Madagascar. J Med Virol 2007; 79 (8): 1082-1088 (Pubitemid 47015406)
222. Oni H. Genotypes of hepatitis C virus in Nigeria. JMed Virol 1996; 49: 178-186
223. Njouom J, Kupfer B, Kochan B, et al. Hepatitis C virus infection and genotypes among human immunodeficiency virus high-risk groups in Cameroon. J Med Virol 2002; 66: 179-186 (Pubitemid 34020067)
224. Njouom R, Nerrienet E, Dubois M, et al. The hepatitis C virus epidemic in Cameroon: genetic evidence for rapid transmission between 1920 and 1960. Infect Gen Evol 2007; 7: 361-367
225. Kabay S, Dutta U, Karen B, et al. Molecular epidemiology of hepatitis C in Australia. J Gastroent Hepatol 1998; 13: 914-920
226. McCaw R, Moaven L, Locarnini SA, et al. Hepatitis C virus genotypes in Australia. J Viral Hepat 1997; 4: 351-357
227. Hofmann H. Genotypes and virus load in patients with hepatitis C infection. Infection 1995; 23: 133-138
228. Woodfield DG, Harness M, Rix K, et al. Identification and genotyping of hepatitis C virus in injectable and oral drug users in New Zealand. Aust NZ J Med 1994; 24: 47-50
229. Bruno S, CrosignaniA,Maisonneuve P, et al. HepatitisCvirus genotype 1b as amajor risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology 2007; 46 (5): 1350-1356 (Pubitemid 350155516)
230. Mondelli MU. Clinical significance of hepatitis C virus genotypes. J Hepatol 1999; 31 Suppl. 16: 65-70 (Pubitemid 30002694)
231. FranchiniM,Mengoli C, Veneri D, et al. Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: a meta-analysis. J Antimicrob Chemother 2008; 61 (6): 1191-1200 (Pubitemid 351753581)
232. Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peg-interferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 470-477 (Pubitemid 44142464)
233. Powis J, Peltekian KM, Lee SS, et al. Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3. J Viral Hepat 2008; 15(1): 52-57 (Pubitemid 350243576)
234. Olinger CM, Lazouskaya NV, Eremin VF, et al. Multiple genotypes and subtypes of hepatitis B and C viruses in Belarus: similarities with Russia and western European influences. Clin Microbiol Infect 2008; 14 (6): 575-581
235. Silini E, Bono F, Cividini A, et al. Molecular epidemiology of hepatitis C virus infection among intravenous drug users. J Hepatol 1995; 22: 691-695
236. Krekulova L, Rehak V, Madrigal N, et al. Genotypic and epidemiologic characteristics of hepatitis C virus infections among recent injection drug user and nonuser populations. Clin Infect Dis 2001; 33: 1435-1438 (Pubitemid 32955203)
237. Chen CH, Sheu JC, Wang JT, et al. Genotypes of hepatitis C virus in chronic liver disease in Taiwan. J Med Virol 1994; 44 (3): 234-236 (Pubitemid 24352261)
238. Wu CH, Lee MF, Kuo HS. Distribution of hepatitis C virus genotypes among blood donors in Taiwan. J Gastroenterol Hepatol 1997; 12: 625-628 (Pubitemid 27504877)
239. Jonsson JR, Purdie DM, Clouston AD, et al. Recognition of genetic factors influencing the progression of hepatitis C: potential for personalized therapy. Mol Diag Ther 2008; 12: 209-218
240. Dustin LB, Rice CM. Flying under the radar: the immunobiology of hepatitis C. Annu Rev Immunol 2007; 25: 71-99
241. Dustin ML, Dustin LB. The immunological relay race: B cells take antigen by synapse. Nature Immunol 2001; 2: 480-482
242. Semmo N, Klenerman P. CD4+ T cell responses in hepatitis C virus infection. World J Gastroenterol 2007 Sep 28; 13 (36): 4831-4838 (Pubitemid 47496748)
243. Blackburn SD, Shin H, Haining WN, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009; 10: 29-37
244. Nakamoto N, Kaplan DE, Coleclough J, et al. Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology 2008; 134: 1927-1937 (Pubitemid 351783250)
245. Radziewicz H, Ibegbu CC, Fernandez ML, et al. Liver-infiltrating lymphocytes in chronic human HCV infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol 2006; 81: 2545-2553 (Pubitemid 46447020)
246. Urbani S, Amadei B, Tola D, et al. PD-1 expression in acute HCV infection is associated with HCV-specific CD8 exhaustion. J Virol 2006; 80: 11398-11403 (Pubitemid 44706581)
247. Mizukoshi E, Eisenbach C, Edlin BR, et al. HCV-specific immune responses of frequently exposed long-term injection drug users. J Inf Dis 2008; 198: 203-212
248. Zeremski M, Shu MA, Brown Q, et al. Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users. J Viral Hepat 2009; 16: 10-20
249. Singh R, Kaul R, Kaul A, et al. A comparative review of HLA associations with hepatitis B and C viral infections across global populations. World J Gastroenterol 2007; 13: 1770-1787 (Pubitemid 46706009)
250. Khakoo SI, Thio CL, Martin MP, et al. HLA andNK cell inhibitory receptor genes in resolving HCV infection. Science 2004; 305: 872-874
251. Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood 2008; 112: 1557-1569
252. Rowan AG, Fletcher JM, Ryan EJ, et al. HCV-specific Th17 cells are suppressed by virus-induced TGF-beta. J Immunol 2008; 181: 4485-4494
253. Ma D, Zhu X, Zhao P, et al. Profile of Th17 cytokines (IL-17, TGF-b, IL-6) and Th1 cytokine (IFN-g) in patients with immune thrombocytopenic purpura. Ann Hematol 2008; 87: 899-904
254. Neuman MG, Sha K, Esguerra R, et al. Inflammation and repair in viral hepatitis C. Dig Dis Sci 2008; 53: 1468-1487
255. Rushbrook SM, Hoare M, Alexander GJ. T-regulatory lymphocytes and chronic viral hepatitis. Expert Opin Biol Ther 2007; 7: 1689-1703 (Pubitemid 350157495)
256. Ward SM, Fox BC, Brown PJ, et al. Quantification and localization of FOXP3+ T lymphocytes and relation to hepatic inflammation during chronic HCV infection. J Hepatol 2007; 47: 316-324
257. Li S, Jones KL, Woollard DJ, et al. Defining target antigens for CD25+ FOXP3+IFN-gamma-regulatory T cells in chronic hepatitis C virus infection. Immunol Cell Biol 2007; 85: 197-204
258. Ebinuma H, NakamotoN, Li Y, et al. Identification and in vitro expansion of functional antigen-specific CD25+ FoxP3+ regulatory T cells in hepatitis C virus infection. J Virol 2008; 82: 5043-5053 (Pubitemid 351657064)
259. Dolganiuc A, Szabo G. T cells with regulatory activity in hepatitis C virus infection: what we know and what we do not. J Leukoc Biol 2008; 84: 614-622
260. Chang S, Dolganiuc A, Szabo G. TLR1 and 6 are involved in TLR2-mediated macrophage activation of HCV core and NS3 proteins. J Leukocyte Biol 2007; 82: 479-487
261. Billerbeck E, Bottler T, Thimme R. Regulatory T cells in viral hepatitis. World J Gastroenterol 2007 Sep 28; 13 (36): 4858-4864
262. Manigold T, Racanelli V. T-cell regulation by CD4 regulatory T cells during hepatitis B and C virus infections: facts and controversies. Lancet Infect Dis 2007 Dec; 7 (12): 804-813 (Pubitemid 350152043)
263. Godkin A, Ng WF, Gallagher K, et al. Expansion of hepatitis C-specific CD4+CD25+ regulatory T cells after viral clearance: a mechanism to limit collateral damage? J Allergy Clin Immunol 2008; 121: 1277-1284
264. Smyk-Pearson S, Golden-Mason L,Klarquist J, et al. Functional suppression by FoxP3+CD4+CD25(high) regulatory T cells during acute hepatitis C virus infection. J Infect Dis 2008; 197: 46-57
265. Li W, Krishnadas DK, Kumar R, et al. Priming and stimulation of hepatitis C virus-specific CD4+ and CD8+ T cells against HCV antigens NS4, NS5a or NS5b from HCV-naive individuals: implications for prophylactic vaccine. Int Immunol 2008 Jan; 20 (1): 89-104
266. Ferri C, Antonelli A, Mascia MT, et al. B-cells and mixed cryoglobulinemia. Autoimmun Rev 2007 Dec; 7 (2): 114-120
267. Kessel A, Toubi E. Chronic HCV-related autoimmunity: a consequence of viral persistence and lymphotropism. Curr Med Chem 2007; 14 (5): 547-554 (Pubitemid 46477727)
268. Ni J, Hembrador E, Di Bisceglie AM, et al. Accumulation of B-lymphocytes with a naïve, resting phenotype in a subset ofHCVpatients. J Immunol 2003; 170: 3429-3439 (Pubitemid 36302223)
269. Stamataki Z, Shannon-Lowe C, Shaw J, et al. Hepatitis C virus association with peripheral blood B lymphocytes potentiates viral infection of liverderived hepatoma cells. Blood 2009; 15: 585-593
270. Mos L, Plesa A. Aspects of immune nonspecific and CD19+ cell changes in alcoholic liver disease with or without chronic hepatitis C virus infection. Rom J Gastroenterol 2003; 12 (4): 267-272 (Pubitemid 38111860)
271. Keck ZY, Li TK, Xia J, et al. Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies. J Virol 2008; 82: 6061-6066 (Pubitemid 351822282)
272. Chua BY, Eriksson EM, Brown LE, et al. A self-adjuvanting lipopeptidebased vaccine candidate for the treatment of hepatitis C virus infection. Vaccine 2008; 26: 4866-4875
273. Keck ZY, MachidaK, LaiMM,et al. Therapeutic control of hepatitis C virus: the role of neutralizing monoclonal antibodies. Curr Top Microbiol Immunol 2008; 317: 1-38
274. Klade CS, Wedemeyer H, Berg T, et al. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology 2008; 134: 1385-1395 (Pubitemid 351615373)
275. Martin P, Simon B, Lone YC, et al. A vector-based minigene vaccine approach results in strong induction of T-cell responses specific of hepatitis C virus. Vaccine 2008; 26: 2471-2481
276. Yerly D, Heckerman D, Allen TM, et al. Increased cytotoxic T-lymphocyte epitope variant cross-recognition and functional avidity are associated with hepatitis C virus clearance. J Virol 2008; 82: 3147-3153 (Pubitemid 351329204)
277. Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol 2009; 21: 317-337
278. Hopkins PA, Sriskandan S. Mammalian Toll-like receptors: to immunity and beyond. Clin Exp Immunol 2005; 140: 395-407 (Pubitemid 40813950)
279. Dolganiuc A, Garcia C, Szabo G. Distinct TLR expression in monocytes and T cells in chronic HCV infection. World J Gastroenterol 2006; 12:1198-1204
280. Machida K, Cheng KTH, Sung VMH, et al. HCV induces TLR4 expression, leading to enhanced production of beta interferon and IL-6. J Virol 2006; 80: 866-874
281. Riordan SM, Skinner NA, Kurtovic J, et al. TLR expression in chronic HCV: correlation with pro-inflammatory cytokine levels and liver injury. Inflamm Res 2006; 55: 279-285 (Pubitemid 44359131)
282. Sato K, Ishikawa T, Okumura A, et al. Expression of TLRs in chromic HCV infection. J Gastroenterol Hepatol 2006; 22: 1627-1632
283. Takayuki Y, Tatsuya K, Michiyo I, et al., Reduced expression and functional impairment of TLR2 on dendritic cells in chronic HCV infection. Hepatol Res 2006; 34: 156-162
284. Kanto T, Hayashi N. Innate immunity in HCV infection: interplay among dendritic cells, killer cells, and natural killer T cells. Hepatol Res 2007; 37 Suppl. 3: S319-26 (Pubitemid 47570639)
285. Kanto T. Virus associated innate immunity in liver. Front Biosci 2008; 13: 6183-6192
286. Miyazaki M, Kanto T, Inoue M, et al. Impaired cytokine response in myeloid dendritic cells I chronic HCV infection regardless of enhances expression of TLRs and RIG-I. J Med Virol 2008; 80: 980-988
287. Villacres MC, Literat O, DeGiacomo M, et al. Defective response to TLR-3 and -4 ligands by activated monocytes in chronic HCV infection. J Viral Hepat 2008; 15: 137-144
288. Hutchinson MR, Bland ST, Johnson KW, et al. Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. Sci World J 2007; 7: 98-111
289. EidAJ, Brown RA, Paya CV, et al. Association between TLR polymorphisms and the outcome of liver transplantation for chronic HCV. Transplantation 2007; 84: 511-516
290. Lankenau SE, Clatts MC. Ketamine injection among high-risk youth: preliminary findings from New York City. J Drug Issues 2002; 32: 893-905
291. Lankenau S, Clatts M. Drug injection practices among high-risk youth: the first shot of ketamine. J Urb Health 2004; 81: 232-248 (Pubitemid 38828806)
292. Lankenau S, Clatts M, Welle D, et al. Street careers: homelessness, drug use, and hustling among young men who have sex with men. Int JDrug Pol 2005; 16: 10-18 (Pubitemid 40128237)
293. Lankenau S, Sanders B, Bloom J, et al. First injection of ketamine among young injection drug users (IDUs) in three US cities. Drug Alcohol Depend 2007; 87: 183-193 (Pubitemid 46223527)
294. Leri F, Bruneau J, Stewart J. Understanding polydrug use: review of heroin and cocaine co-use. Addiction 2003; 98: 7-22 (Pubitemid 36044332)
295. Burgner D, Jamieson SE, Blackwell JM. Genetic susceptibility to infectious diseases: big is beautiful, but will bigger be even better? Lancet Infect Dis 2006; 6: 653-663
296. Ríos-Olivares E, Vilá LM, Reyes JC, et al. Impaired cytokine production and suppressed lymphocyte proliferation activity in HCV-infected cocaine and heroin (''speedball'') users. Drug Alcohol Depend 2006; 85: 236-243
297. Castellano-Higuera A, González-Reimers E, Alemán-Valls MR, et al. Cytokines and lipid peroxidation in alcoholics with chronic hepatitis C virus infection. Alcohol Alcohol 2008; 43: 137-142
298. Napoli J, Bishop GA, McGuinness PH, et al. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of TH1-associated cytokines. Hepatology 1996; 24: 759-765 (Pubitemid 26334270)
299. Fan XG, Liu WE, Li CZ, et al. Circulating TH1 and TH2 cytokines in patients with hepatitis C virus infection. Mediators Inflamm 1998; 7: 295-297 (Pubitemid 28419525)
300. Bansal AS, Bruce J, Hogan PG, et al. Serum soluble CD23 but not IL8, IL10, GM-CSF, or IFN-g is elevated in patients with hepatitis C infection. Clin Immunol 1997; 84: 139-144 (Pubitemid 27353464)
301. Butera D, Marukian S, Iwamaye AE, et al. Plasma chemokine levels correlate with the outcome of antiviral therapy in HCV patients. Blood 2005; 106: 1175-1182
302. Neuman MG, Benhamou JP, Marcellin P, et al. Cytokine-chemokine and apoptotic signatures in patients with hepatitis C. Transl Res 2007; 149: 126-136 (Pubitemid 46298834)
303. Lin Y, Kwon T, Polo J, et al. The induction of broad CD4+ and CD8+ T cell responses and cross-neutralizing antibodies against the hepatitis C virus (HCV) by vaccinating with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1/gpE2 and nonstructural proteins 3, 4 and 5. J Virol 2008; 82: 7492-7503 (Pubitemid 352031217)
304. Li Y, Zhang T, Douglas SD, et al. Morphine enhances HCV replicon expression. Am J Pathol 2003; 163: 1167-1175
305. Wang CQ, Li Y, Douglas SD, et al. Morphine withdrawal enhances HCV replicon expression. Am J Pathol 2005; 167: 1333-1340 (Pubitemid 41541419)
306. Li Y, Ye L, Wang CQ, et al. Morphine inhibits intrahepatic IFN-a expression and enhances complete HCV replication. J Infect Dis 2007; 196: 719-730
307. Bowers MS, McFarland K, Lake RW, et al. Activator of G protein signaling 3: a gatekeeper of cocaine sensitization and drug seeking [comment in Neuron 2004; 42: 181-3]. Neuron 2004; 42: 269-281
308. Chiappelli F, Shapshak P, McCoy C, et al. Cellular immunopathology in alcohol/cocaine co-abusing HIV-1 seropositive African American Women. Front Biosci 2006; 11: 2434-2441
309. Duncan R, Shapshak P, Page JB, et al. Crack cocaine: effect modifier of RNA viral load and CD4 count in HIV infected African American women. Front Biosci 2006; 12: 1488-1495 (Pubitemid 46846847)
310. Gekker G, Hu S, Sheng WS, et al. Cocaine-induced HIV-1 expression in microglia involves sigma-1 receptors and transforming growth factor-beta1. Int Immunopharmacol 2006; 6: 1029-1033
311. Gekker G, Hu S, Wentland MP, et al. Kappa-opioid receptor ligands inhibit cocaine-induced HIV-1 expression in microglial cells. J Pharmacol Exp Ther 2004; 309: 600-606 (Pubitemid 38542613)
312. Peterson PK, Gekker G, Schut R, et al. Enhancement of HIV-1 replication by opiates and cocaine: the cytokine connection. Adv Exp Med Biol 1993; 335: 181-188 (Pubitemid 23294312)
313. Weatherby NL, Kang M, Shapshak P, et al. Screening women for human immunodeficiency virus (HIV) infection using self-reported symptoms: a classification tree analysis. Korean JMeas Eval Phys Educ Sports Sci 2006; 8: 1-15
314. Garten RJ, Lai SH, Zhang JB, et al. Factors influencing a low rate of HCV RNAclearance in heroin users from Southern China. World J Gastroenterol 2008; 14: 1878-1884
315. Hill AVS. Aspects of genetic susceptibility to human infectious diseases. Annu Rev Genet 2006; 40: 469-486 (Pubitemid 44956793)
316. Fried MW, Kroner BL, Preiss LR, et al. Hemophilic siblings with chronic hepatitis C: familial aggregation of spontaneous and treatment-related viral clearance. Multicenter Hemophilia Cohort Study. Gastroenterology 2006; 131: 757-764
317. Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy: definition, nomenclature, diagnosis, and quantification. Final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35: 716-721 (Pubitemid 34183979)
318. Bellamy R, Beyers N, McAdam KP, et al. Genetic susceptibility to tuberculosis in Africans: a genome-wide scan. Proc Natl Acad Sci U S A 2000; 97: 8005-8009 (Pubitemid 30460763)
319. Zhao Q, Sigalov G, Dimitrov V, et al. Detecting SNPs using a synthetic nanopore. Nano Lett 2007 Jun; 7 (6): 1680-1685 (Pubitemid 47140444)
320. Missiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic
321. Papatheodoridis GV, Paraskevis D. Role of genetic polymorphisms in the progression of liver fibrosis in chronic HCV infection. Liver Int 2008; 28: 764-766 (Pubitemid 351818637)
322. Bahr MJ, el Menuawy M, Boeker KH, et al. Cytokine gene polymorphisms and the susceptibility to liver cirrhosis in patients with chronic hepatitis C. Liver Int 2003; 23: 420-425
323. Thursz M. Genetic susceptibility in chronic viral hepatitis. Antiviral Res 2001; 52: 113-116 (Pubitemid 32973685)
324. Pancoska P, Moravek Z, Moll UM. Rational design of DNA sequences for nanotechnology, microarrays and molecular computers using Eulerian graphs. Nucl Acids Res 2004; 32 (15): 4630-4645 (Pubitemid 39317740)
325. Cursino-Santos JR, Donadi EA, Martinelli AL, et al. Evolution of hepatitis C virus infection under host factor influence in an ethnically complex population. Liver Int 2007; 27: 1371-1378
326. Bellamy R. Susceptibility to infectious diseases. In: Bellamy R, editor. The importance of host genetics: advances in molecular cell microbiology (series no. 4). Cambridge: Cambridge University Press, 2004
327. Mueller T, Mas-Marques A, Sarrazin C, et al. Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection. J Hepatol 2004; 41: 652-658 (Pubitemid 39297802)
328. Suneetha PV, Goyal A, Hissar SS, et al. Studies on TAQ1 polymorphism in the 30untranslated region of IL-12P40 gene in HCV patients infected predominantly with genotype 3. J Med Virol 2006; 78: 1055-1060
329. Huang Y, HuiyingY, Brian BB, et al.Afunctional SNP of interferon-g gene is important for interferon-a-induced and spontaneous recovery from HCV infection. Proc Natl Acad Sci U S A 2007; 104: 985-990 (Pubitemid 46154723)
330. Majda-Stanis"awska E, Pietrzak A, Brzezińska-B"aszczyk E. Serum IL-18 concentration does not depend on the presence of HCV-RNA in serum or in PBMC. Hepatogastroenterology 2008; 55: 212-215
331. An P, Thio CL, Kirk GD, et al. regulatory polymorphisms in the interleukin- 18 promoter are associated with hepatitisCvirus clearance. J Infect Dis 2008; 198: 1159-1165
332. Bouzgarrou N, Hassen E, Schvoerer E, et al. Association of interleukin-18 polymorphisms and plasma level with the outcome of chronic HCV infection. J Med Virol 2008; 80: 607-614 (Pubitemid 351358557)
333. Neumann-Haefelin C, Spangenberg HC, Blum HE, et al. Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection. World J Gastroenterol 2007; 13: 4839-4847 (Pubitemid 47496749)
334. Thio CL, Thomas DL, Goedert JJ, et al. Racial differences in HLA class II associations with HCV outcomes. J Inf Dis 2001; 184: 16-21
335. Kuzushita N, Hayashi N, Moribe T, et al. Influence ofHLAhaplotypes on the clinical courses of individuals infected with hepatitis C virus. Hepatology 1998; 27: 240-244 (Pubitemid 28041560)
336. Zavaglia C, Martinetti M, Silini E, et al. Association between HLA class II alleles and protection from or susceptibility to chronic hepatitis C. JHepatol 1998; 28: 1-7 (Pubitemid 28122493)
337. Hong X, Yu RB, Sun NX, et al. Human leukocyte antigen class II DQB1*0301, DRB1*1101 alleles and spontaneous clearance of HCV infection: a meta-analysis. World J Gastroenterol 2005; 11: 7302-7307 (Pubitemid 43137680)
338. Pasta L, Pietrosi G, Marrone C, et al. C4BQ0: a genetic marker of familial HCV-related liver cirrhosis. Dig Liver Dis 2004; 36: 471-477 (Pubitemid 41115451)
339. Richardson MM, Powell E, Barrie HD, et al. A combination of genetic polymorphisms increases the risk of progressive disease in chronic hepatitis C. J Med Genet 2005; 42: e45
340. Saito T, Ji G, ShinzawaH, et al. Genetic variations in humans associated with differences in the course of hepatitis C. Biochem Biophys Res Commun 2004; 317: 335-341 (Pubitemid 38452487)
341. Japanese single nucleotide polymorphisms (JSNP) database [online]. Available from URL: http://snp.ims.u-tokyo.ac.jp/index.html [Accessed 2009 May 19]
342. Hwang Y, Chen EY, Gu ZJ, et al. Genetic predisposition of responsiveness to therapy for chronic hepatitis C. Pharmacogenomics 2006; 7: 697-709 (Pubitemid 44219400)
343. Cormier EG, Durso RJ, Tsamis F, et al. L-SIGN (CD209L) and DC-SIGN (CD209) mediate trans-infection of liver cells by HCV. Proc Natl Acad Sci U S A 2004; 101: 14067-14072 (Pubitemid 39305031)
344. Graham CS,Wells A, Edwards EM, et al. Effect of exposure to injection drugs or alcohol on antigen-specific immune responses in HIV and hepatitis C virus coinfection. J Infect Dis 2007; 195: 847-856
345. Sanai FM, Benmousa A, Al-Hussaini H, et al. Is serum alanine transaminase level a reliable marker of histological disease in chronic hepatitis C infection? Liver Int 2008; 28: 1011-1018
346. Patel K, Nelson DR, Rockey DC, et al. Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis. Clin Gastroenterol Hepatol 2008; 6: 242-247
347. Zaman A, Rosen HR, Ingram K, et al. Assessment of FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patients. Am J Med 2007; 120: 280.e9-14 (Pubitemid 46341167)
348. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-1672
349. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004; 140: 370-381
350. Neuman M. Markers of fibrogenesis in liver disease. Roum J Hepatol 2006; 2: 55-56
351. Hraber P, Kuiken C, Yusim K. Evidence for human leukocyte antigen heterozygote advantage against hepatitis C virus infection. Hepatology 2007; 46: 1713-1721
352. Spada E, Mele A, Berton A, et al. Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance. Gut 2004; 53: 1673-1681 (Pubitemid 39434114)
353. Chang KM, Rehermann B, Chisari FV. Immunopathology of hepatitis C. Springer Semin Immunopathol 1997; 19: 57-68
354. Aberle JH, Formann E, Steindl-Munda P, et al. Prospective study of viral clearance and CD4(+) T-cell response in acute hepatitis C primary infection and reinfection. J Clin Virol 2006; 36: 24-31 (Pubitemid 44360574)
355. Rosen HR, Miner C, Sasaki AW, et al. Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: correlation with clinical disease stages. Hepatology 2002; 35: 190-198 (Pubitemid 34032560)
356. Chander G, Sulkowski MS, Jenckes MW, et al. Treatment of chronic hepatitis C: a systematic review. Hepatology 2002; 36 Suppl. 1: S135-44
357. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358 (9286): 958-965 (Pubitemid 32913521)
358. Hughes CA, Shafran SD. Chronic hepatitis C virus management: 2000-2005 update. Ann Pharmacother 2006; 40: 74-82
359. Dieperink E, Ho SB, Thuras P, et al. A prospective study of neuropsychiatric symptoms associated with interferon-a-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003; 44 (2): 104-112 (Pubitemid 36241123)
360. Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon a: a review. Am J Psychiatry 2000; 157: 867-876 (Pubitemid 30412335)
361. Giunta Brian, Somboonwit C, Tan J, et al. Psychiatric implications of hepatitis-C infection. Crit Rev Neurobiol 2009; 19: 79-118
362. Rosen HR, Weston SJ, Im K, et al. Selective decrease in HCV-specific immunity among African Americans and outcome of antiviral therapy. Hepatology 2007 Aug; 46 (2): 350-358 (Pubitemid 47344769)
363. Cholongitas E, Papatheodoridis GV. Novel therapeutic options for chronic hepatitis C. Aliment Pharmacol Ther 2008; 27: 866-884
364. Labarga P, Soriano V, Vispo ME, et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV infected patients. J Infect Dis 2007; 196: 670-673 (Pubitemid 47293847)
365. Mishchenko EL, Bezmaternykh KD, Likhoshvai VA, et al. Mathematical model of suppression of subgenomic HCV RNA replication in cell culture. J Bioinf Comp Biol 2007; 5: 593-609
366. Pol S, Artu P, Thepot V, et al. Improvement of the CD4 cell count after alcohol withdrawal in HIV-positive alcoholic patients. AIDS 1996; 10: 1293-1297 (Pubitemid 26306612)
367. García-García JA, Mira J, Fernández-Rivera J, et al. Influence of hepatitis C virus coinfection on failure of HIV-infected patients receiving highly active antiretroviral therapy to achieve normal serum b2microglobulin levels. Euro J Clin Microbiol Infect Dis 2003; 22: 194-196 (Pubitemid 36461372)